CervoMed Inc. 8-K

What Happened

• CervoMed Inc. (CRVO) announced in a Form 8-K filed June 18, 2026, that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent covering the Company’s drug candidate neflamapimod for the treatment of dementia with Lewy bodies (DLB) in patients with no substantial Alzheimer’s disease‑like tau pathology. The allowance is expected to provide intellectual property protection into 2042 (without any potential patent term extension).

Key Details

• Regulatory action: Notice of allowance issued by the U.S. Patent and Trademark Office.
• Drug / Indication: Neflamapimod for treatment of dementia with Lewy bodies in patients without substantial Alzheimer’s‑type tau pathology.
• Patent term: Expected protection into 2042 (does not account for any potential patent term extension).
• Filing reference: Reported under Item 8.01 (Other Events) of the Form 8‑K filed 2026-06-18; Item 9.01 (cover page Inline XBRL) was also included.

Why It Matters

• A USPTO notice of allowance strengthens CervoMed’s intellectual property position for neflamapimod in a specific DLB patient population, establishing an expected period of exclusivity through 2042.
• For investors, this is a material milestone for the company’s pipeline and licensing/partnership potential; the filing did not report any accompanying financial results or executive changes.